That other company, after at least a decade of trying to figure out how to get a Phase 1 going, managed to get a chapter published in what MAY be a vanity press offering (in other words, I wonder who wrote the chapter and if NNVC had to remunerate them for it) -- some book purporting to be about nanotechnology. Why would anyone legitimate write a book about a company that can't even get their animal tests done, or decide what disease to focus on? Anyhow that news yesterday is what sent their price up.